Participated · Equity · Aug 2026

Kairos discovery develops KDX-350, an oral anti-cancer drug candidate for which it reports established preclinical proofs of concept. The company is advancing preclinical programs and is fundraising to prepare the project for clinical transition. Leadership and scientific roles include co-founders Alexandre Arnaud (engineer), Alexandre Bancet (CEO), David Neves (CTO) and researcher Léna Marlhoux (PhD student in collaboration with the Centre de recherche en cancérologie de Lyon). The firm launched a hybrid fundraising campaign on Capital Cell to raise €850,000, combining retail investors, a regional fund and a life‑sciences family office, with roughly 80 investors participating by 11 August 2026 and a €1,000 minimum ticket. Kairos discovery's stated plan is to secure a pharmaceutical partner in 2027 and enter clinical phases in 2028, contingent on producing the necessary supporting data and additional financing.

Participated · Equity · Jun 2026

Founded in January 2021 in Andalusia, DynamicsVR develops an immersive VR platform for rehabilitation that integrates gamified therapeutic protocols and remote monitoring for clinicians. Its solution targets musculoskeletal, post-surgical and neurological conditions (including stroke) and can be used both in-clinic and at home under professional prescription. The company reports commercial traction with more than 150 clinics, hospitals and occupational health insurers in Spain and a cited 94% year-over-year growth in business volume. DynamicsVR plans to use its latest €1.3M round to expand into Europe and North America, hire and reinforce its team, and add telemedicine and AI features to the platform. The company positions itself as a software-first player without dependency on proprietary hardware, which it sees as an advantage for faster geographic scaling. Its funding history includes early support (~€78k), a €250k round in 2022 and €225k from ENISA prior to the 2026 raise.

Participated · Equity · Apr 2026

Predictheon is developing an artificial intelligence platform aimed at giving anesthesiologists a single screen with the information they need and the ability to warn of imminent complications. The company was founded by Dr. Pedro Gambús together with physicians Sebastián Jaramillo and Jose Fernando Valencia, and is led by CEO Eva Gubern. Current plans focus on obtaining regulatory approval, initiating clinical trials and running additional pilot deployments, with a target of reaching a minimum market state around 2028. The startup has a small team of nine people and expects modest headcount growth to about 10–11 this year. Financially, it recently secured €1.8 million to fund these next development and commercialization steps. Predictheon is already engaging in discussions with large medical-equipment companies about potential partnerships, distribution deals or exits, and the company does not intend to handle a global commercial strategy entirely on its own.

Participated · Series A · Dec 2025

Based in Clermont-Ferrand with offices in Lyon, Axoltis Pharma researches and develops innovative treatments for neurodegenerative and neurotraumatic diseases. Its lead asset, NX210c, is a 12-amino-acid cyclic peptide derived from SCO-Spondin that promotes blood–brain barrier restoration, offers neuroprotection, and enhances neurotransmission. The candidate holds orphan-drug designations from both the FDA and the EMA and demonstrated a favorable safety profile in a 2023 Phase 1b study. NX210c is now being evaluated in the Phase 2 SEALS trial in 82 ALS patients across 16 investigational centers, with results expected in Q2 2026. Proceeds from the latest capital raise will fund completion of this study and support exploratory work in additional neurological indications. The compound is protected by seven patents owned by Axoltis, and the company is actively pursuing a global pharmaceutical partnership, targeting discussions at the 2026 JP Morgan Healthcare Conference. While the company has not yet disclosed revenue, its financing underscores investor confidence in the differentiated technology and market potential.

Led · Equity · Oct 2025

EVerZom is a biotechnology company building a proprietary GMP-compliant bioproduction platform to generate therapeutic exosomes from mesenchymal stem cells. Its approach couples exosomes with biomaterials to improve delivery and efficacy across multiple indications. The lead candidate, EVerGel, targets Crohn’s complex perianal fistulas and is scheduled to enter the clinic in 2026, while Eviv is in pre-clinical development for acute-on-chronic liver failure (ACLF). Additional exploratory programs span ophthalmology, broader regenerative medicine applications, and extra-pharma opportunities such as cosmetics and veterinary health. Proceeds from the latest round will finance the first clinical trial of EVerGel, extend the platform into hepatology and dermatology, and further scale industrial manufacturing capabilities. No revenue or user metrics have been disclosed to date.